McMaster researchers testing cancer vaccine

A cancer vaccine with the potential to treat incurable patients has started stage one trials in Hamilton. The joint project between McMaster University, Juravinski Hospital and two Ottawa hospitals started enrolling patients earlier this year.

Researchers have developed two specially engineered viruses that trigger the immune system to attack cancer cells without disturbing healthy cells. They also work as vaccines to prevent relapse.

Currently, one patient is being treated in Hamilton and another will start treatment at the end of the month. Seven patients are being treated in Ottawa.

So far, each person is receiving just one of the two viruses. Soon, doctors will start giving patients both viruses, which is a world first in this type of experimental therapy.

Researcher Brian Lichty believes doubling up will help focus the body’s immune response on the cancer. “So we use one virus that expresses or produces one target antigen that’s in the tumour and then we come back with another virus that expresses the same thing. The immune system focuses on the same part, not the virus.”

These viruses only work on tumours that carry a protein called MAGE-A3, including certain melanomas, lung cancers and colorectal cancers.

CHCH’s Elise Copps will have more on this story tonight on the Evening News at 6.


Commenting Guidelines

  • Comments are open for 2 days only after publication of article
  • All comments subject to approval
    • Comments must be constructive and a minimum of 5 words
    • Please do not submit multiple identical comments
    • Personal attacks will not be posted
    • We reserve the right to edit submissions for spelling, grammar, and language
  • CH-CHing! points will be awarded upon submission, however comments will not appear live until they have been approved
  • During the approval process, we reserve the right to withdraw CH-CHing! points awarded to you for comments that do not meet the above guidelines


Teri-Lyn says:

As a cancer survivor, I find this very promising news!

Bob says:

Good news the clinical trials start even at 50% the success rate is miles ahead of what we have now.